Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 7/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 6/20 | 0.42 |
| ▸ | CMA1 | P23946 | 3/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20484554 | 1.00 | MALT1 (0.52) | MALT1EPHA2ELANECMA1XIAP | |
| SCHEMBL22798205 | 1.00 | MALT1 (0.52) | MALT1EPHA2ELANECMA1XIAP | |
| SCHEMBL20484549 | 1.00 | MALT1 (0.52) | MALT1EPHA2ELANECMA1XIAP | |
| SCHEMBL20484548 | 0.97 | MALT1 (0.50) | MALT1EPHA2ELANECMA1XIAP | |
| SCHEMBL22798276 | 0.97 | MALT1 (0.50) | MALT1EPHA2ELANECMA1XIAP | |
| SCHEMBL22798279 | 0.97 | MALT1 (0.50) | MALT1EPHA2ELANECMA1XIAP | |
| Trifluoroacetic Acid SCHEMBL20484535 | 0.96 | MALT1 (0.49) | MALT1EPHA2ELANECMA1CTSG | |
| Trifluoroacetic Acid SCHEMBL20484532 | 0.96 | MALT1 (0.49) | MALT1EPHA2ELANECMA1CTSG | |
| Trifluoroacetic Acid SCHEMBL20484536 | 0.96 | MALT1 (0.49) | MALT1EPHA2ELANECMA1CTSG | |
| SCHEMBL20484708 | 0.92 | MALT1 (0.46) | MALT1EPHA2XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20180251489-A1 | MALT1 INHIBITORS AND USES THEREOF | Cornell University Cornell Center for Technology Enterprise & Commercialization (CCTEC) (US) | 2018-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251489-A1 | MALT1 INHIBITORS AND USES THEREOF | MALT1, BCL3, BCL6 | MALT1 1/4885EPHA2 4333/4885ELANE 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.